Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1974 Aug;27(2):255-69.

Tests for penicillin allergy in man. II. The immunological cross-reaction between penicillins and cephalosporins

Tests for penicillin allergy in man. II. The immunological cross-reaction between penicillins and cephalosporins

E S Assem et al. Immunology. 1974 Aug.

Abstract

The immunological cross-reaction between penicillins and a cephalosporin derivative (cephaloridine CEPR) has been investigated. Cross-allergenicity was studied in twenty-four patients with established penicillin allergy using a variety of tests. Skin tests, quantitative leucocyte challenge (estimating histamine release by allergen) and lymphocyte stimulation (transformation) tests were performed, using CEPR, conjugates of CEPR with human serum albumin (HSA) and bovine gamma-globulin (BGG), benzylpenicillin and benzylpenicilloyl (BPO) conjugates with HSA and BGG. A cross-reaction was clearly established in the majority of patients. The highest percentage of positive results (cross-allergenicity) was obtained in the leucocyte challenge test (80 per cent with CEPR.BGG), followed by the lymphocyte stimulation test (50 per cent with CEPR.BGG), and then the skin test (46 per cent with CEPR.HSA). None of ten non-allergic controls gave a positive result in these tests. Three of the penicillin allergic patients had received cephaloridine, and all three developed allergic reactions. Cross-antigenicity has also been shown by haemagglutination and haemagglutination-inhibition tests on serum from larger groups of penicillin-allergic patients (including the previously mentioned twenty-four patients), and of non-allergic controls, who had anti-BPO antibodies.

PubMed Disclaimer

References

    1. N Engl J Med. 1966 May 5;274(18):998-1002 - PubMed
    1. Immunology. 1966 Jan;10(1):21-33 - PubMed
    1. J Immunol. 1966 Apr;96(4):719-26 - PubMed
    1. Arch Intern Med. 1967 Feb;119(2):141-5 - PubMed
    1. Immunology. 1967 Apr;12(4):417-29 - PubMed

MeSH terms

LinkOut - more resources